M-CSF (CSF1): Macrophage Colony-Stimulating Factor Governing Monocyte/Macrophage Differentiation, Osteoclastogenesis, and Tumor Microenvironment Remodeling via CSF1R/FMS Signaling in Research

# M-CSF (CSF1): Macrophage Colony-Stimulating Factor Governing Monocyte/Macrophage Differentiation, Osteoclastogenesis, and Tumor Microenvironment Remodeling via CSF1R/FMS Signaling in Research

Discovery, Molecular Biology, and Isoforms

The human CSF1 gene maps to chromosome 1p13.3 and encodes three biologically active protein products generated by alternative splicing and proteolytic processing:

Secreted glycoprotein M-CSF (sM-CSF, 256 aa): Primarily produced by exon 6 splicing; the dominant circulating form (plasma levels 1–3 ng/mL). Heavily N-glycosylated (4 N-glycan sites), exists as an antiparallel disulfide-linked homodimer of ~70–90 kDa; individual monomers are ~35–45 kDa depending on glycosylation. The receptor-binding domain maps to the N-terminal 150 amino acids forming a helical bundle.

Cell-surface transmembrane M-CSF (tmM-CSF, 554 aa): Membrane-anchored form with an extended extracellular domain; shed from the surface by ADAM10/17 metalloprotease cleavage to generate cell-associated shorter soluble forms. tmM-CSF provides juxtacrine signaling — direct cell-to-cell M-CSF delivery important in bone marrow niche, thymic epithelium, and placental trophoblast-macrophage crosstalk.

Chondroitin sulfate proteoglycan M-CSF (csM-CSF): Glycosaminoglycan-modified form that binds extracellular matrix; provides depot storage in the hematopoietic microenvironment and slow-release gradient for HSC niche maintenance.

The primary cellular sources of M-CSF include stromal fibroblasts, osteoblasts, endothelial cells, uterine epithelium, and tumor cells. Circulating M-CSF is primarily produced by hepatocytes. Inflammation (TNF, IL-1β, LPS) strongly induces M-CSF expression from stromal cells, providing a paracrine signal to amplify macrophage numbers at sites of infection or injury.

CSF1R Receptor: Architecture and Downstream Signaling

CSF1R (c-FMS, CD115) is a 972-amino acid class III receptor tyrosine kinase encoded by CSF1R on chromosome 5q32 — in a cluster with PDGFRA, PDGFRB, and KIT (all class III RTKs). The receptor architecture mirrors the KIT structure:

Five extracellular Ig-like domains (D1–D5): D2–D3 constitute the M-CSF–binding site; D4 mediates receptor:receptor homotypic contacts stabilizing the activated dimer. The dimeric M-CSF homodimer engages two CSF1R molecules simultaneously, pre-organizing the 2:2 signaling complex.

Juxtamembrane (JM) domain: Autoinhibitory; inserts into the kinase domain in inactive state — analogous to KIT. Mutations at the D4 interface or JM domain constitutively activate CSF1R (found in leukemia).

Split kinase domain with kinase insert (KI): Kinase insert domain (encoded by exons 12–14) contains key regulatory phosphotyrosines. The activation loop Asp796-Phe-Gly797-Leu798 (DFG motif) switches between inactive/active conformations.

Upon M-CSF binding, CSF1R homodimerizes and trans-autophosphorylates on multiple cytoplasmic tyrosines:

Y699 (PI3K p85 docking): Major survival and proliferation signal; PI3K→PIP3→PDK1→AKT→mTORC1 drives macrophage survival, glucose metabolism (GLUT1 upregulation), and oxidative burst. PI3K/AKT is the dominant M-CSF signal in macrophage survival/proliferation.

Y723 (GRB2/GAB2 → RAS/MAPK): ERK1/2 activation drives proliferation; RAS→RAF→MEK→ERK targets include ELK1, RSK, FOS/JUN (AP-1 transcription factors driving cytokine/CSF1 gene expression). AP-1 auto-induces CSF1R expression, creating positive feedback.

Y807 (activation loop phosphorylation): Required for full kinase activity; Y807 phosphorylation stabilizes the "active" DFG-in conformation.

Y559 and Y974 (CBL E3 ligase docking): CBL ubiquitinates CSF1R for internalization and degradation — the primary negative feedback controlling surface receptor density. CSF1R internalization is rapid (t1/2 ~20 min); receptor recycling vs. degradation determines sensitivity.

STAT1 and STAT3: Activated directly by JAK1/2 recruited to CSF1R; STAT3 drives M2/anti-inflammatory macrophage polarization genes (IL-10, arginase-1, CD206/mannose receptor); STAT1 drives M1/pro-inflammatory responses when activated by IFN-γ co-stimulation.

PLCγ2: Generates DAG→PKC and IP3→Ca²⁺; contributes to actin cytoskeleton reorganization (critical for macrophage migration/phagocytosis) and NFAT activation.

SRC/LYN: Activated downstream of CSF1R; mediates cytoskeletal remodeling (podosomes in osteoclasts), FcγR-independent phagocytosis, and anti-apoptotic BCL-2 family upregulation.

Monocyte/Macrophage Differentiation and Tissue Macrophage Maintenance

M-CSF is the master cytokine governing monocyte production in bone marrow and tissue macrophage maintenance throughout adult life. The macrophage differentiation cascade: HSC → CMP → GMP → monocyte progenitor (MoP) → classical monocyte (CD14++/CD16−) → intermediate monocyte (CD14++/CD16+) → non-classical monocyte (CD14+/CD16++). CSF1R expression is first detectable at the MoP stage and progressively increases through monocyte differentiation.

Tissue macrophage populations — microglia, Kupffer cells, alveolar macrophages, peritoneal macrophages, Langerhans cells — are established during fetal development from yolk sac and fetal liver progenitors and maintained by local M-CSF from stromal cells throughout life. Unlike blood monocytes (which turn over rapidly), tissue macrophages can self-renew locally in a CSF1R-dependent manner without continuous monocyte input in steady state. CSF1R-dependent survival signals are thus tonically required for macrophage tissue homeostasis.

Osteoclastogenesis: CSF1R and RANK/RANKL Cooperation

Osteoclasts — the multinucleated bone-resorbing cells — require M-CSF/CSF1R and RANK/RANKL signaling coordinately for differentiation from monocyte/macrophage precursors. M-CSF provides:

• •Proliferation and survival of osteoclast precursors
• •Induction of RANK (receptor activator of NF-κB) expression on precursors — making them competent to respond to RANKL from osteoblasts/stromal cells
• •Cytoskeletal remodeling (via SRC/LYN) required for podosome ring formation and ruffled border during bone resorption

The Csf1op mouse has absent osteoclasts (in addition to absent macrophages), causing severe osteopetrosis — bones are radiographically dense, fracture easily, and marrow cavities are obliterated. This phenotype is partially rescued by M-CSF injection. The osteopetrotic phenotype differs from RANK/RANKL knockout (which has no osteoclast differentiation despite macrophage precursors being present), confirming that both M-CSF/CSF1R and RANK/RANKL are independently required for osteoclastogenesis.

M-CSF in the Tumor Microenvironment (TME)

Tumor-associated macrophages (TAMs) are the most abundant immune cells in many solid tumors and correlate with poor prognosis. Tumors produce large amounts of M-CSF (CSF1), CCL2 (MCP-1), and VEGF to recruit and polarize monocytes/macrophages toward an M2-like protumorigenic phenotype characterized by:

• •Immunosuppression (IL-10, TGF-β, PD-L1 upregulation, IDO expression)
• •Angiogenesis promotion (VEGF, MMP-9, angiopoietin-1 secretion)
• •Extracellular matrix remodeling (MMP-2, MMP-7, cathepsins)
• •Direct suppression of CD8+ T cells and NK cells via IL-10, TGF-β, and arginase-1-mediated arginine depletion

In human clinical trials, anti-CSF1R + anti-PD-1 combination (cabiralizumab + nivolumab) showed promising early signals in pancreatic ductal adenocarcinoma (PDAC) — a tumor type with dense TAM infiltration and poor response to immunotherapy alone. The Phase II PANGOLIN trial (2022) reported objective responses in ~20% of pretreated PDAC patients, though larger confirmatory trials have been initiated.

Tenosynovial Giant Cell Tumor (TGCT): CSF1R Driver Oncogene

Tenosynovial giant cell tumor (TGCT, formerly pigmented villonodular synovitis) is a locally aggressive neoplasm of tendon sheaths and synovium characterized by a pathognomonic chromosomal translocation t(1;2)(p13;q35) fusing COL6A3 (chromosome 2) to CSF1 (chromosome 1). This creates a CSF1 gene fusion that drives constitutive CSF1 overexpression in a small neoplastic clone, which in turn recruits large numbers of CSF1R+ macrophages/giant cells — the dominant cellular component by mass. TGCT represents a unique oncogenic mechanism where a growth factor (CSF1) rather than a receptor is the driver, and the tumor mass consists primarily of reactive recruited cells rather than the oncogenic clone itself.

Pexidartinib (PLX3397, Turalio): a small molecule CSF1R/KIT/FLT3 inhibitor, became the first FDA-approved systemic therapy for TGCT in August 2019. The ENLIVEN trial demonstrated an objective response rate of 38% (15% complete response) with pexidartinib vs. 0% with placebo (Tap et al., 2019, Lancet). Hepatotoxicity (including serious cholestatic events) led to a REMS program requirement. CSF1R inhibition depletes the macrophage/osteoclast cellular mass of the tumor, causing regression of synovial lesions.

Research Tools and Experimental Models

IL-34: The Second CSF1R Ligand

A second CSF1R ligand, IL-34 (interleukin-34), was discovered in 2008 (Lin et al., Science PMID: 18467591) through a systematic screen of orphan ligand-receptor pairs. IL-34 has no sequence homology to M-CSF but binds the same CSF1R extracellular domain (D2–D3) and activates identical intracellular signaling. IL-34 is produced primarily by keratinocytes, neurons, and astrocytes — distinct cellular sources from M-CSF — and is the dominant CSF1R ligand for:

• •Brain microglia (driven by neuronal IL-34; brain M-CSF levels are low)
• •Langerhans cells of the epidermis (driven by keratinocyte IL-34)
• •Kupffer cell local maintenance (both IL-34 and M-CSF contribute)

This dual-ligand biology means that experiments using Csf1−/− mice may not fully recapitulate CSF1R deficiency in brain/skin contexts, while Csf1r−/− mice represent complete CSF1R loss. Anti-CSF1R therapeutics block both M-CSF and IL-34 effects simultaneously.

M-CSF in Reproduction and Placentation

M-CSF and CSF1R are highly expressed in the uterine endometrium and trophoblast during implantation and placentation. Uterine natural killer (uNK) cells and decidual macrophages require M-CSF for differentiation and accumulation. Csf1op/Csf1op female mice have impaired placentation and reduced litter sizes — trophoblast invasion is supported by macrophage-derived MMP-9, and M-CSF promotes trophoblast proliferation directly via CSF1R expression on trophoblasts. This reproductive biology makes CSF1R inhibitor safety in pregnancy a critical clinical consideration.

Current Research Frontiers

Brain microglia and neurodegeneration: Microglial CSF1R signaling maintains microglial survival and self-renewal; microglia depletion via dietary PLX5622 followed by repopulation (CSF1R inhibitor withdrawal) enables near-complete microglial replacement with donor-derived cells in chimeric studies. CSF1R LOF mutations cause adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) — a rare autosomal dominant neurodegenerative disease, validating CSF1R as essential for adult microglial maintenance.

Macrophage-targeting in cancer: Beyond TAM depletion, CSF1R inhibitor combinations with radiation, chemotherapy, and targeted therapy are being evaluated. An unresolved question is whether TAM depletion alone is sufficient or whether repolarization (toward M1) achieves better anti-tumor effects. Anti-CSF1R + anti-CD47 ("do not eat me" signal) combinations aim to enhance macrophage-mediated phagocytosis of tumor cells.

Osteoporosis and bone metastasis: M-CSF is a key driver of osteoclast-mediated bone loss in postmenopausal osteoporosis and osteolytic bone metastases. While RANKL-targeted denosumab is the clinical standard, CSF1R inhibition offers a complementary target, particularly in RANKL-independent osteoclast activation contexts.

Metabolic disease: Adipose tissue macrophages (ATMs) maintain adipose homeostasis; M-CSF-driven ATM polarization toward inflammatory M1 macrophages contributes to insulin resistance in obesity. CSF1R inhibition in diet-induced obese mice reduces ATM numbers and improves insulin sensitivity in preclinical studies.

Conclusion

M-CSF (CSF1) and its receptor CSF1R (c-FMS) constitute the master regulatory axis for monocyte/macrophage biology throughout hematopoiesis, tissue homeostasis, bone remodeling, and immune surveillance. The Csf1op mouse model — silent in the literature for decades — remains one of the most informative single-gene knockouts in immunology, revealing the complete dependence of the macrophage/osteoclast system on a single growth factor signal. The CSF1 fusion oncogene mechanism in TGCT, the therapeutic success of pexidartinib, and the expanding immuno-oncology pipeline targeting TAMs through CSF1R demonstrate how fundamental macrophage biology translates into precision medicine. As single-cell technologies reveal the full complexity of tissue macrophage heterogeneity and IL-34-driven microglial circuits, the CSF1R pathway continues to define new therapeutic opportunities across oncology, neurodegeneration, and metabolic disease.

References

1. Kawasaki ES, Ladner MB, Wang AM, et al. Molecular cloning of a complementary DNA encoding human macrophage-specific colony-stimulating factor (CSF-1). Science. 1985;230(4722):291-296. PMID: 2996129

2. Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell. 1985;41(3):665-676. PMID: 4005137

4. Dai XM, Ryan GR, Hapel AJ, et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 2002;99(1):111-120. PMID: 11756160

5. Lin H, Lee E, Hestir K, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320(5878):807-811. PMID: 18467591

6. Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846-859. PMID: 24898549

7. Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057-5069. PMID: 25082815

8. Tap WD, Wainberg ZA, Anthony SP, et al. Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428-437. PMID: 26222558

10. Elmore MR, Najafi AR, Koike MA, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82(2):380-397. PMID: 24742461

---

FOR RESEARCH USE ONLY. Not for human or veterinary use. Not for diagnostic or therapeutic applications. All biological activity data are derived from in vitro and preclinical studies; results may not predict human clinical outcomes. Information is provided for educational and research purposes only.